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The contribution of adipose tissue an autocrine and endocrine organ in the pathogenesis of infectious disease and metabolic
syndrome is gaining attention. Adipose tissue and adipocytes are one of the major targets of T. cruzi infection. Parasites are
detected 300 days postinfection in adipose tissue. Infection of adipose tissue and cultured adipocytes triggered local expression
of inﬂammatory mediators resulting in the upregulation of cytokine and chemokine levels. Adipose tissue obtained from
infected mice display an increased inﬁltration of inﬂammatory cells. Adiponectin, an adipocyte speciﬁc protein, which exerts
antiinﬂammatory eﬀects, is reduced during the acute phase of infection. The antiinﬂammatory regulator peroxisome proliferator
activated receptor-γ (PPAR-γ) is downregulated in infected cultured adipocytes and adipose tissue. T. cruzi infection is associated
with an upregulation of signaling pathways such as MAPKs, Notch and cyclin D, and reduced caveolin-1 expression. Adiponectin
null mice have a cardiomyopathy and thus we speculate that the T. cruzi-induced reduction in adiponectin contributes to the
T. cruzi-induced cardiomyopathy. While T. cruzi infection causes hypoglycemia which correlates with mortality, hyperglycemia is
associatedwithincreasedparasitemiaandmortality.TheT.cruzi-inducedincreaseinmacrophages inadiposetissuetaken together
with the reduction in adiponectin and the associated cardiomyopathy is reminiscent of the metabolic syndrome.
Copyright © 2009 Fnu Nagajyothi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Diseases caused by nematodes and protozoa have been
reported to be associated with nutritional deﬁciencies,
wasting, and diabetes. An association between human Try-
panosoma cruzi infection (Chagas disease) and obesity and
diabetes has been suspected.
Chagas disease is an important cause of morbidity and
mortality in Latin America where 10% to 30% of infected
individuals eventually succumb to the chronic manifes-
tations such as cardiomyopathy and/or mega syndromes.
This infection is also an opportunistic infection in those
individualswhoareimmunosuppressedincludingthosewith
HIV/AIDS. Although the pathogenesis of Chagas disease
has been investigated by many laboratories the role of the
adipocyte and of adipose tissue has been ignored.
2. The AdipocyteandAdipose Tissue:
GeneralConsiderations
The contribution of the adipocyte or fat cell to the patho-
genesis of diabetes, obesity and the metabolic syndrome
is well recognized [1–5]. Adipose tissue is not a mere
storage compartment for triglycerides. Adipocytes or fat
cells are active endocrine cells that play an important2 Interdisciplinary Perspectives on Infectious Diseases
role in energy homeostasis and the immune system [6].
Adipocytes inﬂuence systemic lipid homeostasis through the
production and release of adipocyte-speciﬁc and adipocyte-
enriched hormonal factors, inﬂammatory mediators such as
cytokines,chemokines,andextracellularmatrixcomponents
also known as adipokines. The strong proinﬂammatory
potential of adipose tissue suggests an important role in the
systemic innate immune response.
Although the most prominent cell type in adipose tissue
is the adipocyte, there are other cell types such as ﬁbroblasts,
endothelial cells, smooth muscle cells and inﬂammatory
cells. Diﬀerent adipose tissue depots display distinct gene
expression patterns and vary widely in size and proximity to
neighboring organs. Although diﬀerences exist between the
diﬀerent fat pads, the depots share similarity with respect
to their ability to store lipids and secrete adipose tissue-
derived hormones. Adipose tissue stores lipid in the form of
triglycerides and also stores mostly nonesteriﬁed cholesterol
on the surface of the lipid droplets that represent specialized
organelles inside the adipocyte.
The potential endocrine function of adipose tissue was
ﬁrst appreciated with the report that the serine protease
adipsin was secreted by the cultured 3T3-L1 adipocytes
[7]. Subsequently, several additional adipokines have been
discovered [8, 9]. These adipokines contribute to the
regulation of energy homeostasis through eﬀects on both
central and peripheral tissues. Several of these adipokines
also contribute to nonmetabolic processes in the body
emphasizing the fact that adipokines participate in the
coordination of multiple physiological functions in a vari-
ety of tissues. The most adipocyte-speciﬁc adipokine is
adiponectin. Other adipokines can also be synthesized by
tissues other than adipose tissue and/or by cells other than
adipocytes.
Systemicenergyhomeostasisismaintainedbycompeting
eﬀe c t so fan u m b e ro fd i ﬀerent hormonal factors, some
of which originate in adipose tissue. These adipocyte-
derived factors (adipokines), inﬂuence processes such as
food intake, energy expenditure and insulin sensitivity in a
variety of tissues. Two adipokines, resistin and adiponectin
have opposite eﬀects on whole-body glucose homeostasis [1,
10]. Pharmacological doses of recombinant resistin hyper-
activate gluconeogenesis through decreased hepatic insulin
sensitivity.
Adiponectin, a hormone exclusively produced by the
adipocytes,isa30-kDamoleculewiththreedeﬁneddomains.
Both intracellular and extracellular adiponectin exists in
three diﬀerent higher order complexes: high molecular
weight form (HMW; 12 to 36mer), and low molecular
weight form (hexamer and trimeric). The diﬀerent com-
plexes exert distinct functions, and the ratio of HMW to
the other forms serves as an independent predicting factor
for metabolic disorders. The total level and HMW ratio
are decreased in obese patients and obese mouse models.
This suggests that adiponectin, especially the HMW form,
m a yb ei n v o l v e di no b e s i t y - r e l a t e dd i s o r d e r s .I th a sb e e n
demonstrated that adiponectin increases insulin sensitivity
byinhibitinghepaticglucoseoutput.Lowerlevelsofcirculat-
ing adiponectin are associated with increased susceptibility
to a variety of diseases of metabolic dysfunction including
diabetes, hypertension and obesity.
There is an association between circulating adiponectin
levels and various metabolic parameters regulating insulin
sensitivity in many diﬀerent patient populations. For exam-
ple, there is a decrease in plasma adiponectin concentration
in obese humans [11]. Other studies showed that this
ﬁnding could be extended to obese rodents and other animal
models. The pattern of decreased adiponectin secretion with
increasing adiposity has been well recognized. There is a
reduction in the levels of adiponectin in diabetics with
coronary artery disease compared with diabetics without
coronary artery disease and the adiponectin levels in serum
are negatively correlated with basal metabolic rate, plasma
glucose and insulin and serum triglycerides [12]. Inter-
estingly, even a relatively moderate weight loss led to a
signiﬁcant increase in circulating adiponectin levels in both
diabetics and nondiabetics. In morbidly obese individuals
[13] undergoing gastric partition surgery, a decrease in basic
metabolic rate was noted and fasting glucose and insulin
levels were associated with a similar increase in circulating
levels of adiponectin together with an increase in insulin
sensitivity.
Adiponectin expression and/or secretion may be directly
or indirectly regulated by plasma insulin levels. Previous
studies have demonstrated that insulin treatment of 3T3-
L1 adipocytes results in signiﬁcantly decreased adiponectin
expression [14], and serum adiponectin levels are inversely
proportional to fasting insulin levels. A corollary is that a
feedback inhibitory pathway must exist that downregulates
expression and secretion of adiponectin in obesity. Intra-
abdominal and mesenteric fat pads (central fat pads) are
predominant sources of systemic adiponectin in the lean




Individuals with the highest levels of adiponectin had a
reduced risk of myocardial infarction compared with those
with the lowest adiponectin levels. Animal models have
corroborated these observations, demonstrating the impor-
tanceofadiponectinforpreventingdiet-inducedprogression
of atherosclerosis. It should be noted, however, that the
mechanism of the antiatherosclerotic activity of adiponectin
has not been entirely elucidated. It has been hypothesized
that adiponectin has inﬂammatory-modulating activities,
and clinical studies have demonstrated an inverse rela-
tionship between adiponectin levels and serum markers of
inﬂammation [15, 16]. It is reported that antiinﬂammatory
eﬀects on both endothelium and macrophages with the
physiologically relevant full-length form exist [4, 9]. It is
unclear whether adiponectin itself has antiinﬂammatory
properties. However, adiponectin production by adipose
tissue can be inhibited by systemic inﬂammation, at least
under some circumstances.
Adiponectin production by adipocytes in culture is in-
hibitedbyinﬂammatorycytokinessuchasTNF-α[9,17]andInterdisciplinary Perspectives on Infectious Diseases 3
this inhibition may be mediated in part by NFκB signaling.
IκB Kinase inhibition leads to increased plasma adiponectin
levels and an improvement in systemic insulin sensitivity
[18]. The antiinﬂammatory activity of adiponectin may be
mediated by its principal signaling target, the AMP-activated
protein kinase (AMPK).
Chemokines positively control the secretion of leptin
suggesting a role for chemokines in the regulation of
adipose tissue and suggest a novel therapeutic basis for
the treatment of obesity, diabetes and cachexia [19]. A
high-fat diet increases the expression of inﬂammatory
genes including early induction of MCP-1 and MCP-3
[20]. The antiatheromatous eﬀects of adiponectin may be
mediated by antiinﬂammatory activities acting directly on
the vasculature. For example, Okamoto et al. [21] recently
reported that adiponectin inhibits the production of CXCR-
3 chemokine ligands in macrophages and causes a reduction
in T-lymphocyte recruitment.
Adiponectin contributes toward protection against car-
diac hypertrophy in cardiac overload states including hyper-
tension, hypertrophic cardiomyopathy, and ischemic heart
disease. In mice, adiponectin protects against myocar-
dial ischemia-reperfusion injury and overload as well as
adrenergically-induced cardiac myocyte hypertrophy, by
inhibiting hypertrophic signals via AMPK [22–24]. Notably,
adiponectin null mice have a cardiomyopathic phenotype
[22, 25]. Thus, the current information is consistent with the
idea that adiponectin is antiinﬂammatory and reduced levels
of adiponectin are proinﬂammatory.
4. Adipose TissueAdipocytesand Infection
The relationship between adipocytes and infectious agents
has only recently received attention. For example, there
have been investigations into the infectious etiologies of
obesity [26]. A role for adipose tissue in infection was also
underscored by the work of the Scherer laboratory who
demonstrated that injection of LPS into mice that were
rendered fatless by manipulation of the apoptosis pathway
did not cause immediate death of mice as they did in
control mice with a normal component of adipose tissue
[27]. These observations suggested that the inﬂammatory
mediators resulting from adipose tissue play an important
role in the inﬂammatory response to infection. One of the
most intensively investigated areas in the interface between
infection and adipose tissue has been in HIV/AIDS [28–31].
5. Trypanosoma cruzi Infection
The relationship between blood sugar and T. cruzi infection
has undergone limited investigation. Studies from our labo-
ratory demonstrated that when mice with chemical-induced
diabetes were infected with T. cruzi, they had a higher
parasitemiaandmortalityandthiswasreversedbytreatment
with insulin [32]. T. cruzi-infected obese diabetic db/dbmice
also displayed a high parasitemia and increased mortality
[32]. The underlying pathophysiological mechanisms of
these observations remain unknown. Recently,we infected
mice and observed hypoglycemia which generally correlated
with mortality [33]. Interestingly, the metabolic response to
bacterialsepsisishyperglycemia,insulinresistance,profound
negative nitrogen balance, and diversion of protein from
skeletal muscle to splanchnic tissues. Thus, the response
to T. cruzi infection diﬀers from that generally observed
in bacterial sepsis. It is possible that there is an eﬀect on
glucose metabolism due to invasion of the liver by the
parasite. During acute infection, glucose levels in all the
T. cruzi-infected mice were below the levels measured for
the control mice. Even though the baseline glucose levels in
the infected animals were lower, the oral glucose tolerance
test indicated relatively normal ability to clear the ingested
glucose despite the high degree of inﬂammation associated
with this infection.
Infection of mice with T. cruzi results in hypoglycemia.
This may be a result of increased uptake of glucose by the
parasite [34]. Another explanation is an eﬀect on glucose
metabolism due to invasion of the liver by the parasite. The
precise mechanism(s) for hypoglycemia during the acute
infection is not known.
Adiponectin levels were signiﬁcantly reduced during
T. cruzi infection of several diﬀerent strains of mice (see
[10] and unpublished observations). Reduced levels of
adiponectin are usually associated with insulin resistance,
hyperglycemia, and obesity, that is, the metabolic syndrome.
Decreased levels of adiponectin are observed in the setting
of some types of inﬂammation and cardiovascular disease.
Acute inﬂammation induced by endotoxemia does not aﬀect
adiponectinlevels[18].Theinfection-inducedhypoglycemia
cannot be readily explained by changes in adiponectin.
Thus, this is an interesting example of a physiologically
relevant condition that combines hypoglycemia and normal
glucose tolerance with signiﬁcantly reduced adiponectin
levels. The decreased insulin levels observed during infection
in the mouse model of T. cruzi infection are consistent
with a physiological response to the very low glucose levels.
Leptin levels were also signiﬁcantly reduced in infected
mice compared to controls [33]. Resistin levels, another
fat cell-speciﬁc secretory factor with insulin-desensitizing
properties, were not aﬀected by infection [33]. Levels of
plasminogen activator inhibitor-1, which is also prominently
expressed in adipocytes, were completely unaﬀected by
infection. Proinﬂammatory markers such as cytokines and
chemokines were markedly elevated in the adipose tissue of
acutely infected mice and persisted into the chronic phase.
Initially, the signiﬁcant decrease in leptin levels was
surprising since the infected mice gained more weight than
the control mice. Magnetic resonance imaging studies as
well as the body composition studies using an ECHO
magnetic resonance spectrometry (MRS) body composition
instrument revealed a decrease in abdominal adipose tissue.
Mice that had marked right ventricular dilation had a greater
loss of fat depots. The weight gain in infected mice appeared
toberelatedtoedema,whichmayhavebeentheconsequence
of right-sided heart failure [33].
CD-1 and FVB mice infected with the Brazil strain
of T. cruzi displayed a reduction in plasma levels of
adiponectin suggesting that infection of adipocytes may also4 Interdisciplinary Perspectives on Infectious Diseases
have consequences on other proteins synthesized in adipose
tissue. The level of adiponectin in adipose tissue was also
reduced during acute infection in a number of fat pads
known to be important sources of adiponectin. During
acute infection, the acute-phase reactants α-1 acid glyco-
protein and SAA3, which are expressed in adipocytes, were
upregulated. Consistent with the infection-induced increase
in inﬂammatory mediators (cytokines and chemokines)
there was a concomitant reduction in adiponectin and
peroxisomeproliferator-activatedreceptor-γ (PPAR-γ).Both
of these proteins are negative regulators of the inﬂammatory
pathway.
We also demonstrated by qPCR that T. cruzi DNA in
adipose tissue 300 days post infection was at the same
levels as in the heart [33]. This observation suggests that
the adipocyte may serve as an important target for T. cruzi
and in chronic Chagas disease adipocytes may represent
an important long-term reservoir for parasites from which
relapse of infection can occur.
Next our laboratory performed in vitro studies to
evaluate the role of the adipocyte in T. cruzi infection in
a model system devoid of many other cell types ordinarily
found in adipose tissue. We were not the ﬁrst group to
observe T. cruzi in adipocytes [35] but we were the ﬁrst
group to investigate this relationship in detail [33, 36].
Adipocytes infected for 96 hours maintain their integrity
and intracellular amastigotes are observed as monitored
by electron microscopy (Figure 1). T. cruzi infection of
cultured adipocytes displays an inﬂammatory phenotype.
For example, there was increased expression of chemokines
such as CCL2, CCL3, CCL5, and CXCL10 and the cytokines
TNF-α, IL-10, and interferon-γ. The expression of SAT3, an
important downstream mediator of cytokine signaling, was
increased as well. Toll-like receptors (TLRs) TLR-2 and -9
reported to be activated during T. cruzi infection of other cell
types were also upregulated in adipocytes T. cruzi infection
also activated ERK and p38 MAPK.
T. cruzi infection of cultured adipocytes resulted in
increased expression of cyclin D1. Cyclin D1 is generally
associated with cell proliferation but cultured adipocytes are
usually terminally diﬀerentiated. The increased expression of
cyclin D1 is important because it is upregulated by ERK and
inversely regulated by caveolin-1 [37]. In infected cultured
adipocytes, we demonstrated that infection resulted in a
reduction in the expression of caveolin-1 and activation
of ERK; both of these events increase the expression of
cyclin D1. The reduction in caveolin-1 expression has also
been demonstrated to be associated with an increased
proinﬂammatory cytokine response [38, 39]. Interestingly,
infection activates the Notch pathway which regulates the
expression of cyclin D1 [40].
PPAR-γ is expressed in adipose tissue and similar to
adiponectin is antiinﬂammatory [41, 42]. As noted, the
reduction in the level of adiponectin is associated with
an increase in inﬂammation [9]. In addition, there is an
inverse relationship between PPAR-γ and inﬂammation as
well as between PPAR-γ and cyclin D1 [43]. It has been
demonstrated that increased expression of cyclin D1 is






of T. cruzi invading adipocyte. (e) A transmission electron micro-
graph of an uninfected adipocyte. (f)–(h) Electron micrographs of
infected adipocytes. The parasites (arrows) are in close proximity
to the lipid droplets (with permission of the Journal of Biological
Chemistry).
suggests a similar relationship between adiponectin and
PPAR-γ [41,42].Ourobservations clearlydemonstratedthat
T. cruzi infection resulted in a reduction in the expression of
adiponectin and PPAR-γ and an increase in the expression of
cyclin D1 and inﬂammatory mediators.
Infection also results in increased expression of PI-3
kinase and activation of AKT, suggesting that this infection
may induce components of the insulin/IGF-1 receptorInterdisciplinary Perspectives on Infectious Diseases 5
cascade. The upregulation of proinﬂammatory pathways is
generally associated with a downregulation of the insulin
signal transduction pathway [44, 45]. It is not clear what
is responsible for this phenomenon, but it can be observed
with a high degree of reproducibility in these cells. T. cruzi
invasion is facilitated through the activation of host cell PI-
3 kinases in mammalian cells [46]. Human Schwann cells
infected with T. cruzi suppressed host-cell apoptosis through
trans sialidase activity via the PI3k/AKT pathway, suggesting
a role for PI3K/AKT in the pathogenesis of Chagas disease
[47]. Despite the upregulation of some of the components
of the pathway, there were no diﬀerences with respect to
a dose response to insulin in infected cells (unpublished
observations). It remains to be determined whether other
pathways inﬂuenced by insulin may be aﬀected, such as
events leading to diﬀerences in the rate of lipid accumulation
or lipolysis. T. cruzi is likely to have an impact on lipid
pathways in vivo, yet these issues have not been examined
to date.
Our ﬁndings are signiﬁcant since there is a positive
correlation between inﬂammation and insulin resistance.
However, the infection of adipocytes with a parasite that
resides intracellularly is diﬀerent from exposing adipocytes
to conventional proinﬂammatory stimuli such as endotoxin.
The continued intracellular presence of the parasites clearly
has a diﬀerential eﬀect on insulin sensitivity, perhaps by
lowering the levels of one of the critical lipid mediators of
insulin resistance.
Fatandglucosemetabolismareinterrelatedanddysregu-
lated in T. cruzi infection. Adipocytes and adipose tissue rep-
resentanimportanttargetofandreservoirforinfection.This
is a reservoir from which parasites can be reactivated during
periods of immunosuppression. In addition, infection of
the adipocyte and adipose tissue creates an inﬂammatory
phenotype that aﬀects a variety of metabolic processes.
Furthermore, the reduction in the expression of adiponectin
and persistent inﬂammation and PPAR-γ perpetuate the
inﬂammatory phenotype. Since adiponectin null mice have
a cardiomyopathic phenotype it is tempting to suggest that
the reduction in adiponectin and PPAR-γ contributes to the
cardiomyopathy of Chagas disease.
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